BioSyent (CVE:RX) Shares Cross Below 50-Day Moving Average - Should You Sell?

Key Points

• BioSyent Inc. (CVE:RX) shares have crossed below their 50-day moving average of C$11.63, trading at C$11.33 during recent sessions.
• The company has a market capitalization of C$129.59 million and a P/E ratio of 18.39, suggesting moderate valuation metrics.
• BioSyent specializes in the development and sale of pharmaceutical products, particularly those for treating iron deficiency anemia.

BioSyent Inc. (CVE:RX - ) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.63 and traded as low as C$11.32. BioSyent shares last traded at C$11.33, with a volume of 1,300 shares trading hands.

BioSyent Trading Down 0.6%

The stock's 50 day moving average is C$11.63 and its 200-day moving average is C$11.22. The company has a market cap of C$129.59 million, a P/E ratio of 18.39 and a beta of 0.93. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.